AVITA Therapeutics Stock News

Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases financial barriers, supporting broader use of RECELL VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care compa...

LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) on behalf of investors concerning the Company's possible violations of federal securities laws.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

AVITA Medical is building a full-thickness wound workflow. They have the RECELL/RECELL GO, Cohealyx, and PermeaDerm. As a whole, this gives them a holistic platform solution for better clinical integration and market reach in skin and wound recovery. Unfortunately, the US reimbursement transition created a claims backlog. This forced RCEL to cut its 2025 guidance and push cash-flow breakeven to...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ:RCEL) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 7, 2025, AVITA released its second quar...

AVITA Medical, Inc. (NASDAQ:RCEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants James Corbett - CEO, President & Executive Director Presentation Unknown Analyst Okay. Thank you, everybody, for joining us.